This is a working overview of CJC-1295, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-02 and is reviewed periodically as new material appears.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
Engineers have been able to successfully incorporate the AceA and AceB genes into mammalian cells in culture, and the cells were successful in translating and transcribing the genes into the appropriate enzymes, proving that the genes could successfully be incorporated into the cell's DNA without damaging the functionality or health of the cell. However, being able to engineer the pathway into transgenic mice has proven to be difficult for engineers. While the DNA has been expressed in some tissues, including the liver and small intestine in test animals, the level of expression is not high, and not found to be statistically significant. In order to successfully engineer the pathway, engineers would have to fuse the gene with promoters which could be regulated in order to increase the level of expression, and have the expression in the right cells, such as epithelial cells. Efforts to engineer the pathway into more complex animals, such as sheep, have not been effective. This illustrates that much more research needs to be done on the topic, and suggests it is possible that a high expression of the cycle in animals would not be tolerated by the chemistry of the cell. Incorporating the cycle into mammals will benefit from advances in nuclear transfer technology, which will enable engineers to examine and access the pathway for functional integration within the genome before its transfer to animals. There are possible benefits, however, to the cycle's absence in mammalian cells.
The first Polynesian settlers arrived in Tahiti around 400 AD by way of Samoan navigators and settlers via the Cook Islands. Over the period of half a century there was much inter-island relations with trade, marriages and Polynesian expansion with the Islands of Hawaii and through to Rapa Nui. The original Tahitians cleared land for cultivation on the fertile volcanic soils and built fishing canoes. The tools of the Tahitians when first discovered were made of stone, bone, shell or wood. The Tahitians were divided into three major classes (or castes): ariʼi, raʼatira and manahune. Ariʼi were relatively few in number while manahune constituted the bulk of population and included some members who played essential roles in the society. It is estimated that by the first contact with Europeans in 1767 the population of Tahiti was most probably around 110,000 or even reached 180,000. Other Society Islands held probably 15,000-20,000 people. Tahitians divided the day into the periods of daylight (ao) and darkness (pō). There was also a concept of irrational fear called mehameha, translated as uncanny feelings. The healers, familiar with herbal remedies, were called taʼata rāʼau or taʼata rapaʼau. In the 19th century Tahitians added the European medicine to their practice. The most famous Tahitian healer Tiurai, of ariʼi, died at age 83 during the influenza outbreak on Tahiti in 1918.
== History == The World Health Organization defines Health as a state of complete physical, mental and social well-being. This is a utopian and unattainable ideal as Moving the goalposts when an achievement is made. Possibly the first use of the term 'positive health' was in 1924 when it was considered a double positive as health itself is a positive term. In the year 2000, it was described as the ability to cope with biological, Psychological, and social stress, and parameters such as pain-bearing capacity and Vital capacity were suggested as its indicators. In 2008, positive health was explained as a combination of excellent status on biological, subjective, and functional measures, including factors such as optimism, stable marriage, and lower blood pressure level. In 2011, it was defined as one's ability to adapt and self-manage in the face of social, physical, and emotional challenges, and it constituted psycho-social parameters. In 2023, positive health was defined as the ability to live long in good health.[1] An effort has been made to identify major indicators that can objectively measure a person's positive health in this sense.
Ubiquitylation affects cellular process by regulating the degradation of proteins (via the proteasome and lysosome), coordinating the cellular localization of proteins, activating and inactivating proteins, and modulating protein–protein interactions. These effects are mediated by different types of substrate ubiquitylation, for example the addition of a single ubiquitin molecule (monoubiquitylation) or different types of ubiquitin chains (polyubiquitylation).
Sources: en.wikipedia.org
== Signs and symptoms == Symptoms seen on plants infected with this virus can vary depending on the plant. However typical symptoms include vein clearing, mottling, and necrotic lines or etching. Symptoms can occur on leaves and fruit and the plants can become stunted. Like other potyviruses, TEV makes viral inclusions that can be seen in the light microscope if properly stained. This particular potyvirus makes two kinds of inclusions that can be diagnostic in a known host. One of the inclusions is the cylindrical inclusions found in the cytoplasm of infected cells and the second inclusion is found in the nucleus. Neither inclusion type stains in the nucleic acid stain (AzureA). (Inclusions of tobacco etch virus in various hosts.)
==== Earliest research ==== Charles P. Slichter wrote that "In 1955, Redfield showed that the conventional theory of saturation did not properly account for the experimental facts of nuclear resonance in solids...[Redfield] showed that the conventional approach essentially defied the second law of thermodynamics." Redfield studied NMR with Charles Pence Slichter, assisting with early superconductivity experiments at University of Illinois, Urbana and published the Redfield Theory as a postdoc under Nicolaas Bloembergen at Harvard. At first he studied electron removal in argon, hydrogen and crypton, and the movement of electrons in photoconductors, including his doctoral thesis on the Hall effect in diamonds and salt crystals. After his breakthrough work on relaxation theory, he continued to produce papers on nuclear spin relaxation.
Specially marked by cunning, despising their own inheritance in the hope of winning a greater, eager after both gain and dominion, given to imitation of all kinds, holding a certain mean between lavishness and greediness, that is, perhaps uniting, as they certainly did, these two seemingly opposite qualities. Their chief men were specially lavish through their desire of good report. They were, moreover, a race skillful in flattery, given to the study of eloquence, so that the very boys were orators, a race altogether unbridled unless held firmly down by the yoke of justice. They were enduring of toil, hunger, and cold whenever fortune laid it on them, given to hunting and hawking, delighting in the pleasure of horses, and of all the weapons and garb of war. Medieval Latin documents referred to them as Nortmanni, which means "men of the North". This name provides the etymological basis for the modern words "Norman" and "Normandy", with -ia (Normandia, like Neustria, Francia, etc.). After 911, this name replaced the term Neustria, which had formerly been used to describe the region that included Normandy. Today, nordmann (Norwegian pronunciation: ['nuɾmɑn]) in the Norwegian language denotes a Norwegian person. In the Swedish language the word for the Norwegian person is norrman.
== Bibliography == Hall, John (2011). Guyton and Hall Textbook of Medical Physiology (12th ed.). Philadelphia: Saunders/Elsevier. ISBN 978-1-4160-4574-8. Longo, Dan; Fauci, Anthony; Kasper, Dennis; Hauser, Stephen; Jameson, J.; Loscalzo, Joseph (2011). Harrison's Principles of Internal Medicine (18th ed.). McGraw-Hill Professional. ISBN 978-0-07-174889-6. Susan Standring; Neil R. Borley; et al., eds. (2008). Gray's anatomy: the anatomical basis of clinical practice (40th ed.). London: Churchill Livingstone. ISBN 978-0-8089-2371-8. Nicki R. Colledge; Brian R. Walker; Stuart H. Ralston, eds. (2010). Davidson's principles and practice of medicine (21st ed.). Edinburgh: Churchill Livingstone/Elsevier. ISBN 978-0-7020-3085-7.
Acemetacin is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of osteoarthritis, rheumatoid arthritis, lower back pain, and relieving post-operative pain. It is manufactured by Merck KGaA under the tradename Emflex. It is no longer available in the UK (since 2018), however is available in other countries as a prescription-only drug.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.